Return to Summer 2013 AACI Commentary

Antos J, Bertko J, Chernew M, Cutler D, de Brantes F, Goldman D, Kocher B, McClellan M, McGlynn E, Pauly M, Shortell S. Bending the curve through health reform implementation. Am J Manag Care. 2010 Nov;16(11):804-12.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul;86(1):97-100

Cheng SK, Dietrich MS, Dilts DM. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials. Clin Cancer Res. 2011 Apr 1;17(7):1947-55.

Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol. 2006 Oct 1;24(28):4545-52.

Dilts D. US cancer trials may go the way of the Oldsmobile. Nat Med. 2010 Jun;16(6):632

Dilts DM, Cheng SK. The importance of doing trials right while doing the right trials. Clin Cancer Res. 2012 Jan 1;18(1):3-5.

Durivage, Henry. Resource Utilization and Factors Predictive of Success at 8 Cancer Centers Initiated Clinical Trials. AACI-CRI 7/2011.

IOM-clinical trials. (http://www.iom.edu/~/media/Files/Activity%20Files/Disease/NCPF/2011-Mar-21-Implementation-Workshop/Doroshow%20Presentation.pdf)

IOM-sharing data. http://www.ncbi.nlm.nih.gov/books/NBK131772/

Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010 March; 87(3): 356361

Kitterman DR, Cheng SK, Dilts DM, Orwoll ES. The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Acad Med. 2011 Nov;86(11):1360-6.

McClellan M, Benner J, Schilsky R, Epstein D, Woosley R, Friend S, Sidransky D, Geoghegan C, Kessler D. An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov. 2011 Feb;10(2):79-80.

Roberts SA, Karnes EK, Allen JD, Benner JS, Sigal EV, McClellan M. Achieving the goals of effective, safe, and individualized cancer care. Clin Cancer Res. 2011 Nov 1;17(21):6632-3.

Yee D et. al. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20;30(36):4584-6.